| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6827336 | Schizophrenia Research | 2012 | 5 Pages |
Abstract
Add-on agents with alpha-2 antagonist activity appear to improve the efficacy of D2 antagonists for the treatment of schizophrenia by reducing negative symptoms. These results support conducting a more definitive confirmatory clinical trial.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Eric Michael Hecht, David C. Landy,